Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 258Carcinoma, Non-Small-Cell Lung 226Carcinoma, Renal Cell 143Neoplasm Metastasis 97Neoplasms 93Carcinoma, Hepatocellular 85Squamous Cell Carcinoma of Head and Neck 84Colorectal Neoplasms 81Lung Neoplasms 73Stomach Neoplasms 56Pancreatic Neoplasms 56Carcinoma, Transitional Cell 49Hodgkin Disease 47Urinary Bladder Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Head and Neck Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Brain Neoplasms 32Recurrence 27Kidney Neoplasms 27Multiple Myeloma 25Uveal Melanoma 23Esophageal Neoplasms 23Uterine Cervical Neoplasms 22Skin Neoplasms 22

Interventions

pembrolizumab 1Sirolimus 1Nivolumab 1Ipilimumab 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Cancers × Nivolumab × Clear all
NCT03956680 2025-02-19

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Bristol-Myers Squibb

Phase 1 Completed
54 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡